Protalix BioTherapeutics Investor Relations Material
Latest events
Q3 2024
Protalix BioTherapeutics
Access the full event backlog
Slides, Transcripts, and Reports from 11,000+ public companies
Latest reports from Protalix BioTherapeutics Inc
Access all reports
Protalix BioTherapeutics Inc. is a biopharmaceutical company focusing on the development, production, and commercialization of recombinant therapeutic proteins using its proprietary ProCellEx plant cell-based protein expression system. This technology enables the company to produce proteins with clinically improved profiles and to develop a pipeline of proprietary therapeutic proteins aimed at established pharmaceutical markets. Additionally, the company is developing other products, including treatments for cystic fibrosis and Fabry Disease, utilizing its platform to manufacture complex proteins, antibodies, and vaccines. The company is headquartered in Carmiel, Israel, and its shares are listed on the NYSE.
Latest articles
Prada: The Story of an Icon
Prada's journey from a small Milan boutique to a global luxury empire, led by Miuccia's innovation and creativity.
5 Dec 2024
Hims & Hers: Bridging Gaps in Telehealth
Hims & Hers was founded in 2016 by Andrew Dudum and has grown into a ~$4 billion company in the telehealth industry in less than a decade.
5 Dec 2024
Andrew Dudum: Founder and CEO of Hims & Hers
Andrew Dudum is the founder and CEO of Hims & Hers, an innovative telehealth company focused on bridging the gap between consumers and healthcare.
4 Dec 2024
Ticker symbol
PLX
Country
πΊπΈ United States